Researchers have developed a prime editing platform that lets doctors fine-tune cell therapies using drugs already in the hospital pharmacy. The system makes therapeutic T cells resistant to one immunosuppressive drug while keeping them sensitive to another, giving clinicians a built-in "control dial." The study, published in Blood, is now moving toward a first-in-human trial.
A clinician-led team from Australia's WEHI institute has developed a gene-editing platform that could solve one of cell therapy's trickiest problems: keeping therapeutic immune cells alive in patients who also need immunosuppression. Using prime editing — a precise DNA-editing technology — researchers engineered T cells to be resistant to tacrolimus (a common anti-rejection drug) while remaining sensitive to a related drug, cyclosporin. This creates a built-in "control dial," letting clinicians protect the therapeutic cells with one drug while retaining the option to suppress them with another if something goes wrong.
The platform was first tested in cells from patients with SPTCL-HLH, a rare and serious immune-related blood cancer affecting children and young adults. It was then successfully applied to virus-specific T cells and CAR T cells, suggesting broad applicability across cell therapy types. Crucially, the approach relies entirely on drugs already in routine clinical use, lowering the bar for real-world translation.
Key Takeaways:
Why it matters: Millions of patients — from transplant recipients to those with rare immune disorders — need ongoing immunosuppression that can undermine cell therapies. This platform could make cutting-edge cell and gene therapies accessible to a much broader patient population.
